People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Engage Therapeutics, Inc. | — | Pharmaceuticals | Series B | $30.6M | $238.0M | 2019 |
Jouko Isojarvi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jouko Isojarvi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Heath Lukatch | 1 | 10 |
| Gerry Brunk | 1 | 5 |
| Stephen Collins | 1 | 5 |
| Gregory Mayes | 1 | 5 |
| Orrin Devinsky | 1 | 3 |
| Mark Theeuwes | 1 | 3 |
| Warren Lammert | 1 | 3 |
| Gerry D. Brunk | 1 | 2 |
| Stephen D. Collins | 1 | 2 |
| Heath D. Lukatch | 1 | 1 |
| Jouko D. Isojarvi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.